TGFB3 and ovarian endometrioid adenocarcinoma: Nevertheless, with regard to women with endometrioid ovarian cancer, TGF-β3 mRNA expression had no significant effect on OS (HR, 2.44; 95% CI, 0.27–21.89; P = 0.41) or on PFS (HR, 0.49; 95% CI, 0.19–1.23; P = 0.12).